The duration of response to treatment with alefacept has been assessed in patients with moderate to severe chronic plaque psoriasis who responded to alefacept therapy in phase 2 and phase 3 clinical studies. In a phase 2 trial, duration of response was based on time to retreatment with alefacept. In two phase 3 studies, the more objective measure of maintenance of a ≥50% reduction from baseline Psoriasis Area and Severity Index (PASI 50) was used. Two patient subsets were analyzed: (1) those who achieved a PASI 75 at any time during the trials and (2) those who achieved a Physician Global Assessment of “clear” or “almost clear” at any time during the trials. Regardless of the criterion used or the route of alefacept administration (intravenous or intramuscular), the median duration of response to alefacept therapy ranged from 7 to 10 months across the three studies. Alefacept is a remittive therapy for psoriasis.
Get full access to this article
View all access options for this article.
References
1.
KooJLebwohlM. Duration of remission of psoriasis therapies. J Am Acad Dermatol1999; 41:51–59.
2.
McClureSLValentineJGordonKB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf2002; 25:913–927.
3.
LebwohlM. New developments in the treatment of psoriasis. Arch Dermatol2002; 138:686–688.
4.
KaplanRPRussellDHLoweNJ. Etretinate therapy for psoriasis: Clinical responses, remission times, epidermal DNA and polyamine responses. J Am Acad Dermatol1983; 8:95–102.
5.
HeydendaelVMRSpulsPIOpmeerBC. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med2003; 349:658–665.
6.
CollinsPWainwrightNJAmorimI. 8-MOP PUVA for psoriasis: A comparison of minimal phototoxic dose-based regimen with a skin-type approach. Br J Dermatol1996; 135:248–254.
7.
VallatVPGilleaudeauPBattatL. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy. J Exp Med1994; 180:283–296.
8.
PrinzJC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol2003; 17:257–270.
9.
SingriPWestDPGordonKB. Biologic therapy for psoriasis: The new therapeutic frontier. Arch Dermatol2002; 138:657–663.
10.
GottliebABBosJD. Recombinantly engineered human proteins: Transforming the treatment of psoriasis. Clin Immunol2002; 105:105–116.
11.
MillerGTHochmanPSMeierW. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med1993; 178:211–222.
12.
MajeauGRMeierWJimmoB. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol1994; 152:2753–2767.
13.
da SilvaAJBrickelmaierMMajeauGR. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2+ cells. J Immunol2002; 168:4462–4471.
14.
CooperJCMorganGHardingS. Alefacept selectively promotes NK cell-mediated deletion of CD45RO+ human T cells. Eur J Immunol2003; 33:666–675.
15.
EllisCNKruegerGG, for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med2001; 345:248–255.
16.
OrtonneJ-PLebwohlMGriffithsCEM, for the Alefacept Clinical Study Group. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol2003; 13:117–123.
17.
GordonKBVaishnawAKO'GormanJ, for the Alefacept Clinical Study Group. Treatment of psoriasis with alefacept. Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol2003; 139:1563–1570.
18.
ChamianFNovitskayaIKhatcherianA. Therapeutic improvement induced by alefacept is linked to selective elimination of CD3+, CD8+, and CD103+ T cells from skin lesions of psoriasis vulgaris. Poster presented at the Psoriasis from Gene to Clinic 3rd International Symposium, 21–23 November 2002, London.
19.
SandersMEMakgobaMWSharrowSO. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol1988; 140:1401–1407.
20.
MajeauGRWhittyAYimK. Low affinity binding of an LFA-3/IgG1 fusion protein to CD2+ T cells is independent of cell activation. Cell Adhes Commun1999; 7:267–279.
21.
KruegerGGPappKAStoughDB, for the Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol2002; 47:821–833.
22.
LebwohlMChristophersELangleyR, for the Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol2003; 139:719–727.
23.
KruegerGGEllisCN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol2003; 148:784–788.
24.
GordonKBLangleyRG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol2003; 2:624–628.
25.
CarlinCSFeldmanSRKruegerJG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol2004; 50:859–866.
26.
FinlayAYSalekMSHaneyJ, for the Alefacept Clinical Study Group. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology2003; 206:307–315.
27.
FeldmanSRMenterAKooJY, for the Alefacept Clinical Study Group. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol2004; 150:317–326.
